Annual CFI
-$3.31 M
+$13.95 M+80.80%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual cash flow from investing activities is currently -$3.31 million, with the most recent change of +$13.95 million (+80.80%) on 31 December 2023. During the last 3 years, it has fallen by -$2.95 million (-815.75%). EYPT annual CFI is now -124.42% below its all-time high of $13.58 million, reached on 30 June 2017.EYPT Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$16.20 M
+$176.59 M+110.10%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly cash flow from investing activities is currently $16.20 million, with the most recent change of +$176.59 million (+110.10%) on 30 September 2024. Over the past year, it has increased by +$17.92 million (+1041.63%). EYPT quarterly CFI is now -50.80% below its all-time high of $32.92 million, reached on 31 December 2022.EYPT Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$170.54 M
+$17.92 M+9.51%
30 September 2024
Summary:
EyePoint Pharmaceuticals TTM cash flow from investing activities is currently -$170.54 million, with the most recent change of +$17.92 million (+9.51%) on 30 September 2024. Over the past year, it has dropped by -$247.29 million (-322.20%). EYPT TTM CFI is now -301.25% below its all-time high of $84.74 million, reached on 30 June 2023.EYPT TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +80.8% | +1041.6% | -322.2% |
| 3 y3 years | -815.8% | +10000.0% | -10000.0% |
| 5 y5 years | -2411.4% | +100.0% | -10000.0% |
EYPT Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -815.8% | +90.0% | -50.8% | +110.1% | -301.3% | +9.5% |
| 5 y | 5 years | -2411.4% | +90.0% | -50.8% | +110.1% | -301.3% | +9.5% |
| alltime | all time | -124.4% | +90.0% | -50.8% | +110.1% | -301.3% | +9.5% |
EyePoint Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $16.20 M(-110.1%) | -$170.54 M(-9.5%) |
| June 2024 | - | -$160.40 M(-870.9%) | -$188.46 M(+1191.2%) |
| Mar 2024 | - | $20.81 M(-144.1%) | -$14.60 M(+340.3%) |
| Dec 2023 | -$3.31 M(-80.8%) | -$47.15 M(+2641.2%) | -$3.31 M(-104.3%) |
| Sept 2023 | - | -$1.72 M(-112.8%) | $76.75 M(-9.4%) |
| June 2023 | - | $13.47 M(-58.0%) | $84.74 M(+18.9%) |
| Mar 2023 | - | $32.09 M(-2.5%) | $71.26 M(-512.8%) |
| Dec 2022 | -$17.27 M(-47.9%) | $32.92 M(+424.8%) | -$17.27 M(-79.2%) |
| Sept 2022 | - | $6.27 M(<-9900.0%) | -$83.15 M(-7.2%) |
| June 2022 | - | -$12.00 K(-100.0%) | -$89.55 M(-0.0%) |
| Mar 2022 | - | -$56.44 M(+71.2%) | -$89.56 M(+170.4%) |
| Dec 2021 | -$33.12 M(+9049.4%) | -$32.97 M(>+9900.0%) | -$33.12 M(+9417.5%) |
| Sept 2021 | - | -$131.00 K(+424.0%) | -$348.00 K(+0.9%) |
| June 2021 | - | -$25.00 K(<-9900.0%) | -$345.00 K(-0.3%) |
| Mar 2021 | - | $0.00(-100.0%) | -$346.00 K(-4.4%) |
| Dec 2020 | -$362.00 K(+70.0%) | -$192.00 K(+50.0%) | -$362.00 K(+105.7%) |
| Sept 2020 | - | -$128.00 K(+392.3%) | -$176.00 K(+266.7%) |
| June 2020 | - | -$26.00 K(+62.5%) | -$48.00 K(+2.1%) |
| Mar 2020 | - | -$16.00 K(+166.7%) | -$47.00 K(-77.9%) |
| Dec 2019 | -$213.00 K(+61.4%) | -$6000.00(<-9900.0%) | -$213.00 K(+2.9%) |
| Sept 2019 | - | $0.00(-100.0%) | -$207.00 K(-34.5%) |
| June 2019 | - | -$25.00 K(-86.3%) | -$316.00 K(-84.5%) |
| Mar 2019 | - | -$182.00 K(+67.0%) | -$2.04 M(-87.9%) |
| Dec 2018 | -$132.00 K(-99.2%) | - | - |
| Sept 2018 | - | -$109.00 K(-93.8%) | -$16.93 M(+0.3%) |
| June 2018 | -$16.89 M(-224.4%) | -$1.75 M(-88.4%) | -$16.89 M(+32.3%) |
| Mar 2018 | - | -$15.07 M(<-9900.0%) | -$12.76 M(-326.1%) |
| Dec 2017 | - | $0.00(-100.0%) | $5.64 M(-29.7%) |
| Sept 2017 | - | -$64.00 K(-102.7%) | $8.03 M(-40.8%) |
| June 2017 | $13.58 M(-404.3%) | $2.37 M(-28.8%) | $13.58 M(+130.8%) |
| Mar 2017 | - | $3.33 M(+39.7%) | $5.88 M(+47.8%) |
| Dec 2016 | - | $2.39 M(-56.4%) | $3.98 M(+154.5%) |
| Sept 2016 | - | $5.48 M(-203.0%) | $1.56 M(-135.1%) |
| June 2016 | -$4.46 M(-33.7%) | -$5.32 M(-471.3%) | -$4.46 M(>+9900.0%) |
| Mar 2016 | - | $1.43 M(-5217.9%) | -$26.00 K(-99.4%) |
| Dec 2015 | - | -$28.00 K(-94.9%) | -$4.24 M(-41.7%) |
| Sept 2015 | - | -$546.00 K(-38.3%) | -$7.27 M(+8.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | -$6.73 M(<-9900.0%) | -$885.00 K(-68.2%) | -$6.73 M(+7.4%) |
| Mar 2015 | - | -$2.78 M(-9.0%) | -$6.27 M(+9.0%) |
| Dec 2014 | - | -$3.06 M(>+9900.0%) | -$5.75 M(+315.8%) |
| Sept 2014 | - | -$7000.00(-98.3%) | -$1.38 M(-2195.5%) |
| June 2014 | $66.00 K(-99.0%) | -$421.00 K(-81.4%) | $66.00 K(-97.6%) |
| Mar 2014 | - | -$2.26 M(-273.0%) | $2.77 M(-50.5%) |
| Dec 2013 | - | $1.31 M(-9.2%) | $5.59 M(-21.8%) |
| Sept 2013 | - | $1.44 M(-36.8%) | $7.15 M(+12.5%) |
| June 2013 | $6.36 M(+949.2%) | $2.28 M(+307.3%) | $6.36 M(+52.5%) |
| Mar 2013 | - | $560.00 K(-80.5%) | $4.17 M(+12.2%) |
| Dec 2012 | - | $2.87 M(+343.6%) | $3.72 M(+105.9%) |
| Sept 2012 | - | $647.00 K(+611.0%) | $1.80 M(+197.9%) |
| June 2012 | $606.00 K(-106.4%) | $91.00 K(-15.7%) | $606.00 K(-155.5%) |
| Mar 2012 | - | $108.00 K(-88.7%) | -$1.09 M(-70.9%) |
| Dec 2011 | - | $959.00 K(-273.7%) | -$3.75 M(-45.4%) |
| Sept 2011 | - | -$552.00 K(-65.6%) | -$6.88 M(-27.6%) |
| June 2011 | -$9.50 M(+359.1%) | -$1.61 M(-37.1%) | -$9.50 M(-4.6%) |
| Mar 2011 | - | -$2.56 M(+18.2%) | -$9.96 M(+34.5%) |
| Dec 2010 | - | -$2.16 M(-31.9%) | -$7.41 M(+41.2%) |
| Sept 2010 | - | -$3.17 M(+53.5%) | -$5.24 M(+153.5%) |
| June 2010 | -$2.07 M(+961.0%) | -$2.07 M(<-9900.0%) | -$2.07 M(+9752.4%) |
| Mar 2010 | - | $0.00(0.0%) | -$21.00 K(-46.2%) |
| Dec 2009 | - | $0.00(0.0%) | -$39.00 K(-55.7%) |
| Sept 2009 | - | $0.00(-100.0%) | -$88.00 K(-54.9%) |
| June 2009 | -$195.00 K(-24.7%) | -$21.00 K(+16.7%) | -$195.00 K(-35.0%) |
| Mar 2009 | - | -$18.00 K(-63.3%) | -$300.00 K(-8.0%) |
| Dec 2008 | - | -$49.00 K(-54.2%) | -$326.00 K(+14.8%) |
| Sept 2008 | - | -$107.00 K(-15.1%) | -$284.00 K(+9.7%) |
| June 2008 | -$259.00 K(-114.6%) | -$126.00 K(+186.4%) | -$259.00 K(+94.7%) |
| Mar 2008 | - | -$44.00 K(+528.6%) | -$133.00 K(+49.4%) |
| Dec 2007 | - | -$7000.00(-91.5%) | -$89.00 K(+8.5%) |
| Sept 2007 | - | -$82.00 K | -$82.00 K |
| June 2007 | $1.77 M(-142.9%) | - | - |
| June 2006 | -$4.13 M(-32.5%) | - | - |
| June 2005 | -$6.12 M(+1570.0%) | - | - |
| June 2004 | -$366.30 K(+949.6%) | - | - |
| June 2003 | -$34.90 K(-111.1%) | - | - |
| June 2001 | $314.80 K | - | - |
FAQ
- What is EyePoint Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual CFI year-on-year change?
- What is EyePoint Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly CFI year-on-year change?
- What is EyePoint Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals TTM CFI year-on-year change?
What is EyePoint Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of EYPT is -$3.31 M
What is the all time high annual CFI for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual cash flow from investing activities is $13.58 M
What is EyePoint Pharmaceuticals annual CFI year-on-year change?
Over the past year, EYPT annual cash flow from investing activities has changed by +$13.95 M (+80.80%)
What is EyePoint Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of EYPT is $16.20 M
What is the all time high quarterly CFI for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly cash flow from investing activities is $32.92 M
What is EyePoint Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, EYPT quarterly cash flow from investing activities has changed by +$17.92 M (+1041.63%)
What is EyePoint Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of EYPT is -$170.54 M
What is the all time high TTM CFI for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high TTM cash flow from investing activities is $84.74 M
What is EyePoint Pharmaceuticals TTM CFI year-on-year change?
Over the past year, EYPT TTM cash flow from investing activities has changed by -$247.29 M (-322.20%)